Does the media favor DNA or TWST?

In the previous week, Twist Bioscience had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 8 mentions for Twist Bioscience and 2 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.10 beat Ginkgo Bioworks' score of 0.55 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ELVN or DNA?

In the previous week, Enliven Therapeutics had 17 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 19 mentions for Enliven Therapeutics and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.55 beat Enliven Therapeutics' score of 0.31 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNA or IMNM more profitable?

Immunome has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Immunome's return on equity of -51.15% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -215.41% -56.08% -26.06% Immunome N/A -51.15% -47.32%

Does the media favor DNA or IMNM?

In the previous week, Immunome had 7 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 9 mentions for Immunome and 2 mentions for Ginkgo Bioworks. Immunome's average media sentiment score of 0.68 beat Ginkgo Bioworks' score of 0.55 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AUPH or DNA?

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for Ginkgo Bioworks. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Ginkgo Bioworks' score of 0.55 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PHVS or DNA more profitable?

Pharvaris has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Ginkgo Bioworks -215.41% -56.08% -26.06%

Does the media refer more to PHVS or DNA?

In the previous week, Pharvaris had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Pharvaris and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.55 beat Pharvaris' score of 0.34 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Ginkgo Bioworks (DNA) Competitors

$7.87 -0.02 (-0.22%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$7.87 0.00 (-0.01%)

As of 06/12/2026 08:00 PM Eastern

Compare

DNA vs. TWST, ELVN, IMNM, AUPH, and PHVS

Should you buy Ginkgo Bioworks stock or one of its competitors? MarketBeat compares Ginkgo Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ginkgo Bioworks include Twist Bioscience (TWST), Enliven Therapeutics (ELVN), Immunome (IMNM), Aurinia Pharmaceuticals (AUPH), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

How does Ginkgo Bioworks compare to Twist Bioscience?

Ginkgo Bioworks (NYSE:DNA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, media sentiment, profitability and risk.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 3.1% of Twist Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Twist Bioscience has a net margin of -19.85% compared to Ginkgo Bioworks' net margin of -215.41%. Twist Bioscience's return on equity of -26.73% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Twist Bioscience	-19.85%	-26.73%	-19.15%

In the previous week, Twist Bioscience had 6 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 8 mentions for Twist Bioscience and 2 mentions for Ginkgo Bioworks. Twist Bioscience's average media sentiment score of 1.10 beat Ginkgo Bioworks' score of 0.55 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, suggesting that its stock price is 123% more volatile than the broader market.

Twist Bioscience has higher revenue and earnings than Ginkgo Bioworks. Twist Bioscience is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.02	-$312.76M	-$5.36	N/A
Twist Bioscience	$376.57M	12.60	-$77.67M	-$1.33	N/A

Ginkgo Bioworks currently has a consensus price target of $8.50, indicating a potential upside of 7.96%. Twist Bioscience has a consensus price target of $67.00, indicating a potential downside of 12.04%. Given Ginkgo Bioworks' higher possible upside, equities research analysts plainly believe Ginkgo Bioworks is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Twist Bioscience beats Ginkgo Bioworks on 12 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Enliven Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Ginkgo Bioworks	$170.15M	3.02	-$312.76M	-$5.36	N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Enliven Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Enliven Therapeutics' return on equity of -21.04% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Enliven Therapeutics presently has a consensus target price of $61.50, suggesting a potential upside of 33.32%. Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential upside of 7.96%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Enliven Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Enliven Therapeutics had 17 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 19 mentions for Enliven Therapeutics and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.55 beat Enliven Therapeutics' score of 0.31 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Summary

Enliven Therapeutics beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Immunome?

Ginkgo Bioworks (NYSE:DNA) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Immunome has a beta of 2.04, indicating that its share price is 104% more volatile than the broader market.

Immunome has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Immunome's return on equity of -51.15% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Immunome	N/A	-51.15%	-47.32%

In the previous week, Immunome had 7 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 9 mentions for Immunome and 2 mentions for Ginkgo Bioworks. Immunome's average media sentiment score of 0.68 beat Ginkgo Bioworks' score of 0.55 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has lower revenue, but higher earnings than Ginkgo Bioworks. Immunome is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.02	-$312.76M	-$5.36	N/A
Immunome	$6.94M	299.93	-$212.39M	-$2.38	N/A

Ginkgo Bioworks currently has a consensus price target of $8.50, suggesting a potential upside of 7.96%. Immunome has a consensus price target of $33.17, suggesting a potential upside of 80.45%. Given Immunome's stronger consensus rating and higher possible upside, analysts clearly believe Immunome is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 7.2% of Immunome shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Immunome beats Ginkgo Bioworks on 11 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	7.19	$287.20M	$2.17	7.29
Ginkgo Bioworks	$170.15M	3.02	-$312.76M	-$5.36	N/A

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Ginkgo Bioworks' net margin of -215.41%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 2 mentions for Ginkgo Bioworks. Aurinia Pharmaceuticals' average media sentiment score of 1.16 beat Ginkgo Bioworks' score of 0.55 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals currently has a consensus price target of $17.25, indicating a potential upside of 9.04%. Ginkgo Bioworks has a consensus price target of $8.50, indicating a potential upside of 7.96%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Aurinia Pharmaceuticals is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Aurinia Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Ginkgo Bioworks on 13 of the 16 factors compared between the two stocks.

How does Ginkgo Bioworks compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Ginkgo Bioworks (NYSE:DNA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Pharvaris has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 60.10%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential upside of 7.96%. Given Pharvaris' stronger consensus rating and higher probable upside, research analysts plainly believe Pharvaris is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Pharvaris has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, Pharvaris had 4 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Pharvaris and 2 mentions for Ginkgo Bioworks. Ginkgo Bioworks' average media sentiment score of 0.55 beat Pharvaris' score of 0.34 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharvaris has higher earnings, but lower revenue than Ginkgo Bioworks. Pharvaris is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Ginkgo Bioworks	$170.15M	3.02	-$312.76M	-$5.36	N/A

Summary

Ginkgo Bioworks beats Pharvaris on 8 of the 15 factors compared between the two stocks.

Get Ginkgo Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DNA vs. The Competition

Export

Metric	Ginkgo Bioworks	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$514.26M	$3.39B	$6.52B	$23.31B
Dividend Yield	N/A	2.25%	2.67%	4.05%
P/E Ratio	-1.47	20.00	24.00	31.31
Price / Sales	3.02	303.75	533.77	100.04
Price / Cash	N/A	53.61	27.48	18.65
Price / Book	0.90	8.32	10.55	4.69
Net Income	-$312.76M	$23.94M	$3.57B	$1.08B
7 Day Performance	-2.50%	1.84%	0.59%	2.07%
1 Month Performance	2.31%	-0.04%	1.55%	3.44%
1 Year Performance	-11.93%	44.82%	25.41%	24.11%

Ginkgo Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DNA Ginkgo Bioworks	0.8804 of 5 stars	$7.87 -0.2%	$8.50 +8.0%	-11.9%	$514.26M	$170.15M	N/A	640	Positive News
TWST Twist Bioscience	2.0868 of 5 stars	$70.04 +1.2%	$58.00 -17.2%	+127.2%	$4.31B	$376.57M	N/A	990	Positive News Analyst Forecast Gap Up
ELVN Enliven Therapeutics	2.8158 of 5 stars	$33.63 -3.1%	$61.80 +83.8%	+110.5%	$2.11B	N/A	N/A	50	Gap Down
IMNM Immunome	3.6804 of 5 stars	$18.61 +0.2%	$33.17 +78.2%	+99.8%	$2.10B	$6.94M	N/A	40	Analyst Forecast Gap Down
AUPH Aurinia Pharmaceuticals	2.5568 of 5 stars	$15.66 -1.1%	$17.25 +10.2%	+93.4%	$2.04B	$283.05M	7.22	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DNA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, ELVN, IMNM, AUPH, and PHVS

How does Ginkgo Bioworks compare to Twist Bioscience?

Summary

How does Ginkgo Bioworks compare to Enliven Therapeutics?

Summary

How does Ginkgo Bioworks compare to Immunome?

Summary

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Summary

How does Ginkgo Bioworks compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ginkgo Bioworks (DNA) Competitors

DNA vs. TWST, ELVN, IMNM, AUPH, and PHVS

How does Ginkgo Bioworks compare to Twist Bioscience?

Do institutionals and insiders have more ownership in DNA or TWST?

Is DNA or TWST more profitable?

Does the media favor DNA or TWST?

Which has more volatility & risk, DNA or TWST?

Which has better earnings & valuation, DNA or TWST?

Do analysts rate DNA or TWST?

Summary

How does Ginkgo Bioworks compare to Enliven Therapeutics?

Which has better earnings and valuation, ELVN or DNA?

Do insiders and institutionals hold more shares of ELVN or DNA?

Is ELVN or DNA more profitable?

Do analysts rate ELVN or DNA?

Does the media refer more to ELVN or DNA?

Which has more risk and volatility, ELVN or DNA?

Summary

How does Ginkgo Bioworks compare to Immunome?

Which has more volatility & risk, DNA or IMNM?

Is DNA or IMNM more profitable?

Does the media favor DNA or IMNM?

Which has better valuation & earnings, DNA or IMNM?

Do analysts prefer DNA or IMNM?

Do insiders & institutionals hold more shares of DNA or IMNM?

Summary

How does Ginkgo Bioworks compare to Aurinia Pharmaceuticals?

Do insiders and institutionals have more ownership in AUPH or DNA?

Which has preferable earnings & valuation, AUPH or DNA?

Is AUPH or DNA more profitable?

Does the media refer more to AUPH or DNA?

Do analysts prefer AUPH or DNA?

Which has more volatility and risk, AUPH or DNA?

Summary

How does Ginkgo Bioworks compare to Pharvaris?

Which has more volatility & risk, PHVS or DNA?

Do insiders & institutionals have more ownership in PHVS or DNA?

Do analysts prefer PHVS or DNA?

Is PHVS or DNA more profitable?

Does the media refer more to PHVS or DNA?

Which has stronger valuation & earnings, PHVS or DNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNA vs. The Competition

Ginkgo Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools